144 related articles for article (PubMed ID: 32533904)
21. Risk Factors Associated with Cisplatin-Induced Nephrotoxicity in Patients with Advanced Lung Cancer.
Miyoshi T; Misumi N; Hiraike M; Mihara Y; Nishino T; Tsuruta M; Kawamata Y; Hiraki Y; Kozono A; Ichiki M
Biol Pharm Bull; 2016; 39(12):2009-2014. PubMed ID: 27904042
[TBL] [Abstract][Full Text] [Related]
22. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N; Hirsch FR; Luft AV; Szczesna A; Ciuleanu TE; Dediu M; Ramlau R; Galiulin RK; Bálint B; Losonczy G; Kazarnowicz A; Park K; Schumann C; Reck M; Depenbrock H; Nanda S; Kruljac-Letunic A; Kurek R; Paz-Ares L; Socinski MA;
Lancet Oncol; 2015 Jul; 16(7):763-74. PubMed ID: 26045340
[TBL] [Abstract][Full Text] [Related]
23. Understanding the Risk Factors and Long-Term Consequences of Cisplatin-Associated Acute Kidney Injury: An Observational Cohort Study.
Bhat ZY; Cadnapaphornchai P; Ginsburg K; Sivagnanam M; Chopra S; Treadway CK; Lin HS; Yoo G; Sukari A; Doshi MD
PLoS One; 2015; 10(11):e0142225. PubMed ID: 26556481
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Middleton G; Gridelli C; De Marinis F; Pujol JL; Reck M; Ramlau R; Parente B; Pieters T; Visseren-Grul CM; San Antonio B; John WJ; Zimmermann AH; Chouaki N; Paz-Ares L
Curr Med Res Opin; 2018 May; 34(5):865-871. PubMed ID: 29424248
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
Fukushima T; Wakatsuki Y; Kobayashi T; Sonehara K; Tateishi K; Yamamoto M; Masubuchi T; Yoshiike F; Hirai K; Hachiya T; Koizumi T
Cancer Chemother Pharmacol; 2018 Jun; 81(6):1043-1050. PubMed ID: 29644460
[TBL] [Abstract][Full Text] [Related]
26. The evaluation of urinary calprotectin levels for prediction of acute cisplatin-induced nephrotoxicity.
Koçak G; Bilik G; Yeşilova A; Oyman F; Can M; Cihan Ş
Medicine (Baltimore); 2022 Jul; 101(26):e29814. PubMed ID: 35777022
[TBL] [Abstract][Full Text] [Related]
27. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma.
Camidge DR; Blais N; Jonker DJ; Soulières D; Doebele RC; Ruiz-Garcia A; Thall A; Zhang K; Laurie SA; Chao RC; Chow LQ
Cancer Chemother Pharmacol; 2013 Feb; 71(2):307-19. PubMed ID: 23108697
[TBL] [Abstract][Full Text] [Related]
28. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Yue D; Xu S; Wang Q; Li X; Shen Y; Zhao H; Chen C; Mao W; Liu W; Liu J; Zhang L; Ma H; Li Q; Yang Y; Liu Y; Chen H; Wang C
Lancet Respir Med; 2018 Nov; 6(11):863-873. PubMed ID: 30150014
[TBL] [Abstract][Full Text] [Related]
29. A Randomized Phase 2 Study of 5-Aminolevulinic Acid Hydrochloride and Sodium Ferrous Citrate for the Prevention of Nephrotoxicity Induced by Cisplatin-Based Chemotherapy of Lung Cancer.
Kawamura K; Matsushima H; Sakai H; Iwashima A; Nakamura S; Kojima T; Sasaki S; Shigenaga T; Natsume I; Sasaki T; Ohsaki Y; Iwanaga K; Nishi K; Mitsuishi Y; Taniguchi H; Sato K; Yamauchi M; Nakajima M; Takahashi K
Oncology; 2022; 100(11):620-632. PubMed ID: 36099876
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
[TBL] [Abstract][Full Text] [Related]
31. Does the number of cycles of cisplatin based chemotherapy have any effect on renal function in patients with testicular germ cell tumor?
Suer E; Mermerkaya M; Gülpınar Ö; Afandiyev F; Baltacı S; Türkölmez K; Bedük Y
J Urol; 2013 Dec; 190(6):2081-5. PubMed ID: 23764076
[TBL] [Abstract][Full Text] [Related]
32. Nephroprotection by theophylline in patients with cisplatin chemotherapy: a randomized, single-blinded, placebo-controlled trial.
Benoehr P; Krueth P; Bokemeyer C; Grenz A; Osswald H; Hartmann JT
J Am Soc Nephrol; 2005 Feb; 16(2):452-8. PubMed ID: 15590762
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
Koba T; Minami S; Nishijima-Futami Y; Masuhiro K; Kimura H; Futami S; Yaga M; Mori M; Kagawa H; Uenami T; Kohmo S; Otsuka T; Yamamoto S; Komuta K; Kijima T
Cancer Chemother Pharmacol; 2018 Jul; 82(1):111-117. PubMed ID: 29728800
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.
Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt W; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Zuna I; Griesinger F; Thomas M;
Ann Oncol; 2013 Apr; 24(4):986-92. PubMed ID: 23161898
[TBL] [Abstract][Full Text] [Related]
36. Safety of a short hydration method for cisplatin administration in comparison with a conventional method-a retrospective study.
Sakaida E; Iwasawa S; Kurimoto R; Ebata T; Imai C; Oku T; Sekine I; Tada Y; Tatsumi K; Takiguchi Y
Jpn J Clin Oncol; 2016 Apr; 46(4):370-7. PubMed ID: 26755829
[TBL] [Abstract][Full Text] [Related]
37. Phase II Study of the Efficacy and Safety of High-dose Pemetrexed in Combination with Cisplatin
He Q; Bi X; Ren C; Wang Y; Zou P; Zhang H; Chi N; Xiu C; Wang Y; Tao R
Anticancer Res; 2017 Aug; 37(8):4711-4716. PubMed ID: 28739776
[TBL] [Abstract][Full Text] [Related]
38. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
39. Pilot study of sequential vinorelbine and cisplatin followed by docetaxel for selected IIIB and stage IV non-small cell lung cancer.
Clark JI; Kancharla K; Qamar R; Fisher S; Hantel A; Panganiban J; Millbrandt L; Albain KS
Lung Cancer; 2001 Nov; 34(2):271-7. PubMed ID: 11679186
[TBL] [Abstract][Full Text] [Related]
40. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y; Motoyama S; Niioka T; Miura M
J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
